Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Business Wire (Tue, 23-Jun 8:30 AM ET)
Globe Newswire (Thu, 14-May 8:30 AM ET)
Globe Newswire (Wed, 13-May 7:11 AM ET)
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
Globe Newswire (Wed, 6-May 8:00 AM ET)
Globe Newswire (Fri, 10-Apr 8:00 AM ET)
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Globe Newswire (Tue, 7-Apr 8:30 AM ET)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 2-Apr 8:00 AM ET)
Globe Newswire (Tue, 31-Mar 8:00 AM ET)
Milestone’s CARDAMYST Approval Delivers First Self-Administered PSVT Solution in Over 30 Years
Market Chameleon (Mon, 15-Dec 4:55 AM ET)
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
Milestone Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol MIST.
As of June 26, 2026, MIST stock price was flat at $1.25 with 408,806 million shares trading.
MIST has a beta of 3.88, meaning it tends to be more sensitive to market movements. MIST has a correlation of 0.31 to the broad based SPY ETF.
MIST has a market cap of $155.62 million. This is considered a Micro Cap stock.
Last quarter Milestone Pharmaceuticals - Common Shares reported $238,000 in Revenue and -$.20 earnings per share. This fell short of revenue expectation by $-45 million and missed earnings estimates by -$.34.
In the last 3 years, MIST traded as high as $3.86 and as low as $.63.
The top ETF exchange traded funds that MIST belongs to (by Net Assets): GWX.
MIST has underperformed the market in the last year with a price return of -33.9% while the SPY ETF gained +22.2%. MIST has also underperformed the stock market ETF in the last 3 month and 2 week periods returning 0.0% and -1.6%, respectively, while the SPY returned +12.1% and -0.2%, respectively.
MIST support price is $1.20 and resistance is $1.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MIST shares will trade within this expected range on the day.